CYTOMX THERAPEUTICS I

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

21 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

18 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

11 Mar 2024 15:10:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

04 Mar 2024 12:12:49 By NetDania Notify

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

01 Mar 2024 12:17:46 By NetDania Notify

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

28 Feb 2024 10:19:37 By NetDania Notify

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

27 Feb 2024 11:18:02 By NetDania Notify

CytomX Therapeutics to Present at Upcoming March Investor Conferences

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

24 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

12 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

21 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

07 Nov 2023 15:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming November Investor Conferences

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

18 Oct 2023 15:30:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming September Investor Conferences

05 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

10 Aug 2023 15:05:00 By Nasdaq GlobeNewswire